Table 1:
Demographics and baseline contraceptive use of cisgender women randomized to receive CAB-LA and received at least one injection in HIV Prevention Trials Network study 077 (N=85)
| Cohort 1 (n=46) | Cohort 2 (n=39) | Overall (n=85) | |
|---|---|---|---|
| Age+ | 26 (23-35) | 31(23-38) | 28 (23-36) |
| BMI+ | 28 (24-35) | 26 (22-35) | 27 (22-35) |
| Race/Ethnicity | |||
| Non-Hispanic black | 24 (52.2%) | 20 (51.3%) | 44 (51.8%) |
| Non-Hispanic white | 12 (26.1%) | 4 (10.3%) | 16 (18.8%) |
| Hispanic/Latino | 9 (19.6%) | 12 (30.8%) | 21 (24.7%) |
| Asian | 0 (0.0%) | 1 (2.6%) | 1 (1.2%) |
| Mixed/Other | 1 (2.2%) | 2 (5.1%) | 3 (3.5%) |
| Region | |||
| United States | 13 (28.3%) | 13 (33.3%) | 26 (30.6%) |
| Sub-Saharan Africa | 26 (56.5%) | 18 (46.2%) | 44 (51.8%) |
| Brazil | 7 (15.2%) | 8 (20.5%) | 15 (17.6%) |
| Contraceptive Type | |||
| None | 2 (4.3%) | 4 (10.3%) | 6 (7.1%) |
| Not of reproductive potential | 5 (10.9%) | 7 (17.9%) | 12 (14.1%) |
| Oral contraceptives | 12 (26.1%) | 6 (15.4%) | 18 (21.2%) |
| Injectable | 12 (26.1%) | 16 (41.0%) | 28 (32.9%) |
| Implants∫ | 6 (13.0%) | 4 (10.3%) | 10 (11.8%) |
| Other∫∫ | 9 (19.6%) | 2 (5.1%) | 11 (12.9%) |
+
Median(IQR)
∫
Implantable = intradermal implant
∫∫
Other = vaginal ring, intrauterine device